Arthur Kuan is going viral. He’s the CEO of Santa Ana, CA biotech company Cold Genesys, which genetically modifies viruses to attack cancer and, as a bonus, bolsters your immune system against it. The venture investor encountered Cold Genesys as a founding member at Hong Kong healthcare fund Ally Bridge Group. Fascinated by the science, Kuan, who holds a master’s degree in biotechnology from Johns Hopkins, joined Cold Genesys as COO. When founder Alex Yeung retired left in 2016, Kuan took over. He’s since launched clinical trials of the biotech’s bladder cancer treatment and has signed a partnership to test its effectiveness with Merck’s immunotherapy drug Keytruda. "I’ve done a good job turning this science story into a real business concept," Kuan says. In March, he closed a $22 million Series C round led by ORI Capital with the China-based medical device maker Lepu Medical, which has the China license for its products.
Read more about the 30 Under 30 honorees in healthcare on Forbes: https://www.forbes.com/sites/leahrosenbaum/2019/12/03/30-under-30-2020-healthcare-at-every-scale/#36faa2572f75
Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1
Stay Connected
Forbes newsletters: https://newsletters.editorial.forbes.com
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbes
Forbes Video on Instagram: http://instagram.com/forbes
More From Forbes: http://forbes.com
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.